about
Treatment of hepatitis C in children: a systematic reviewOutcomes and management of viral hepatitis and human immunodeficiency virus co-infection in liver transplantationEfficacy of antiretroviral therapy programs in resource-poor settings: a meta-analysis of the published literature.Nontuberculous mycobacterial infection in hematopoietic stem cell and solid organ transplant recipients.Granulocyte colony-stimulating factor for hepatitis C therapy-associated neutropenia: systematic review and economic evaluation.The natural history of hepatitis C virus infection acquired during childhood.Hepatitis B and C serologic profiles of Canadian organ donors and recipients: retrospective 10-year review at a single center.Outcomes of Lung Transplantation in Recipients With Hepatitis C Virus Infection.Characterization of hepatitis B virus genotypes and quantitative hepatitis B surface antigen titres in North American tertiary referral liver centres.Epidemiology and risk factors for nosocomial bloodstream infections in solid organ transplants over a 10-year period.Solid organ transplantation from hepatitis B virus-positive donors: consensus guidelines for recipient management.Monitoring of polyomavirus BK virus viruria and viremia in renal allograft recipients by use of a quantitative real-time PCR assay: one-year prospective study.Viral hepatitis in solid organ transplantation.Donor-derived bacteremia in liver transplant recipients despite antibiotic prophylaxis.Treatment of hepatitis C in potential lung transplant candidates.Staphylococcus aureus bacteremia in patients receiving pegylated interferon-alpha and ribavirin for chronic hepatitis C virus infection.Disseminated zygomycosis: a rare cause of infection in patients with hematologic malignancies.An assessment of donor-to-recipient transmission patterns of human cytomegalovirus by analysis of viral genomic variants.A randomized, controlled trial of daclizumab vs anti-thymocyte globulin induction for lung transplantation.Serum immunoglobulins predict the extent of hepatic fibrosis in patients with chronic hepatitis C virus infection.Occult hepatitis B virus infection in a North American community-based population.Prospective monitoring of BK polyomavirus infection early posttransplantation in nonrenal solid organ transplant recipients.The use of donor and recipient screening for toxoplasma in the era of universal trimethoprim sulfamethoxazole prophylaxis.Metagenomics and the case of the deadly hamster.Recommended curriculum for subspecialty training in transplant infectious disease on behalf of the American Society of Transplantation Infectious Diseases Community of Practice Educational Initiatives Working Group.Assessment of adenovirus infection in adult lung transplant recipients using molecular surveillance.Treatment of hepatitis C in a lung transplant recipient with sofosbuvir and daclatasvir.A Prospective Molecular Surveillance Study Evaluating the Clinical Impact of Community-Acquired Respiratory Viruses in Lung Transplant RecipientsComparison of Quantiferon-TB Gold With Tuberculin Skin Test for Detecting Latent Tuberculosis Infection Prior to Liver TransplantationLong-term Outcome of Lung Transplantation in Previous Intravenous Drug Users With Talc Lung GranulomatosisViral Hepatitis in Solid Organ Transplant RecipientsGene Expression of Porcine Lymphotrophic Herpesvirus-1 in Miniature Swine with Posttransplant Lymphoproliferative Disorder
P50
Q21136318-06CFB839-F84B-40B0-8C1B-D681AAB0D2FEQ26864478-52459D96-8EBA-4C9E-A498-DD880E176347Q33988155-0B95226E-BE47-4EAD-AAE4-2B9B95EB68E1Q35779935-CE8A354E-172E-473A-B91C-A8F6F3B42FAFQ37892651-484E9D5B-1CDA-4C9D-9E23-C01EA6B41B00Q37958084-03499F12-4677-4239-A56F-9E9F81BEFEA2Q38844564-569CC37A-B24F-4C1A-8FE5-AF196ECE5B8DQ39902309-C9F8EFEE-802F-4816-BC00-8F2CB8909CACQ40117484-122449A3-0DDA-401F-A273-D3E097FFDA83Q40815339-98897856-10D4-4D65-B9ED-43854352FCCAQ41468537-A439630C-3456-4E9E-ADB6-AD903268132AQ41901051-D4D98432-6A28-4E99-87CE-C6E0DEBBED71Q42272319-534AC074-464B-4616-BB02-0EB265E28019Q42275530-362C004A-4B11-4B37-9215-79DEADE76D07Q43038674-F99EA449-535E-4C55-B46C-59B1CCF597D3Q43039479-8193280B-802D-4FDC-B513-96C58BEA20D5Q44591473-745B505B-4034-457D-9228-63B4BF41B4E8Q44698240-4B0CAB85-C857-4B92-A9E8-309DAD71AB58Q44725787-B4E98660-2D4B-4149-9FF8-7530D5B1F60DQ44874481-4A38C98E-1390-4D58-A74D-15860FDF3A9BQ45499710-2C399DF3-225A-477E-9F43-B8F8D2B1522BQ46518668-B6231854-5516-4DA1-9ED1-BD0698F6F495Q46647741-413FA419-F10F-4691-BF88-71BF4EBFCFB0Q51787402-AF4AA606-9B77-45D3-9C60-047842DC2930Q51904362-8CDA61A4-DC95-4D19-99CA-24EE7A2181ABQ54566425-88D4D7D1-D8EB-4CFC-8E1C-94623200A1ECQ54648351-D091DD3A-34E6-40DA-B7AC-331F86D7833EQ58074817-80FF4204-55B7-4579-BA37-80FA29EAF37EQ58075093-885B886B-15A5-4081-856D-621E2923038EQ58645022-593A3F0A-6E6B-466B-8C13-153C2FFA4741Q58645052-768A5F3D-8720-4E33-973A-75D850A581C8Q58645065-C30AA74A-6BFC-42F9-A20B-F9FB75BA7061
P50
description
hulumtuese
@sq
researcher
@en
wetenschapper
@nl
հետազոտող
@hy
name
Karen Doucette
@ast
Karen Doucette
@en
Karen Doucette
@es
Karen Doucette
@nl
Karen Doucette
@sl
type
label
Karen Doucette
@ast
Karen Doucette
@en
Karen Doucette
@es
Karen Doucette
@nl
Karen Doucette
@sl
prefLabel
Karen Doucette
@ast
Karen Doucette
@en
Karen Doucette
@es
Karen Doucette
@nl
Karen Doucette
@sl
P106
P1153
15135396500
P21
P31
P496
0000-0002-1660-9166